Introduction: Around 85% of non-small cell lung cancers (NSCLCs) are diagnosed at an advanced stage (IIIB to IV), where therapeutic options depend on molecular analysis. However, diagnostic material for molecular testing is often represented by cytological samples which are generally scarce and span a wide range of preparation types. Thus, the primary objective is to efficiently manage materials for molecular profiling. This study aims to evaluate the suitability of different cytological samples to assess morphological and molecular characteristics of advanced NSCLC. Methods: Sixty-seven cytological samples obtained from patients with advanced NSCLC were utilized. The series encompassed different procedure types (fine-needle aspiration cytology, transbronchial needle aspiration, effusions) processed by cell blocks in 54% (n = 36), direct smears in 33% (n = 22), and liquid-based cytology (LBC) in 13% (n = 9). Cytological diagnoses were routinely performed, and molecular analysis was conducted using next-generation sequencing (NGS) and real-time polymerase chain reaction (RT-PCR) methods. Results: Adequate quantity and quality of nucleic acids were obtained from all the samples, allowing molecular profiling. Combined NGS and RT-PCR analysis showed wild-type profiles in 62.7% (n = 42) and mutated profiles in 37.3% (n = 25) of the samples. Kirsten Rat Sarcoma Virus (KRAS) mutations were identified in 19.5% (n = 13) of samples, EGFR mutations in 10.4% (n = 7) and v-raf murine sarcoma viral oncogene homolog B (BRAF) mutations in 2.9% (n = 2). Identified chromosomal alterations were v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) duplication in 2.9% (n = 2). Conclusions: The cytological sample types examined in this study proved to be suitable for molecular testing, in addition to conventional morphologic diagnosis, showing versatility and adaptability to different clinical contexts. Molecular testing on cytological samples is accurate and fast, representing a valid tool for molecular profiling of advanced NSCLC.

1.
D’Ardia
A
,
Caputo
A
,
Fumo
R
,
Ciaparrone
C
,
Gaeta
S
,
Picariello
C
, et al
.
Advanced non-small cell lung cancer: rapid evaluation of EGFR status on fine-needle cytology samples using Idylla
.
Pathol Res Pract
.
2021
;
224
:
153547
.
2.
Zhang
Y
,
Li
J
,
Hua
P
.
Targeted next-generation sequencing in cytology specimens
.
3.
Käsmann
L
,
Taugner
J
,
Eze
C
,
Roengvoraphoj
O
,
Dantes
M
,
Gennen
K
, et al
.
Performance status and its changes predict outcome for patients with inoperable stage III NSCLC undergoing multimodal treatment
.
Anticancer Res
.
2019
;
39
(
9
):
5077
81
.
4.
Lilenbaum
RC
.
Treatment of patients with advanced lung cancer and poor performance status
.
Clin Lung Cancer
.
2004
;
6
(
Suppl 2
):
S71
4
.
5.
Pisapia
P
,
Pepe
F
,
Iaccarino
A
,
Sgariglia
R
,
Nacchio
M
,
Conticelli
F
, et al
.
Next generation sequencing in cytopathology: focus on non-small cell lung cancer
.
Front Med
.
2021
;
8
:
633923
.
6.
Travis
WD
,
Brambilla
E
,
Noguchi
M
,
Nicholson
AG
,
Geisinger
K
,
Yatabe
Y
, et al
.
Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification
.
Arch Pathol Lab Med
.
2013
;
137
(
5
):
668
84
.
7.
Young
K
,
da Cunha Santos
G
,
Card
P
,
Leighl
N
.
The role of cytology in molecular testing and personalized medicine in lung cancer: a clinical perspective
.
Cancer Cytopathol
.
2019
;
127
(
2
):
72
8
.
8.
da Cunha Santos
G
,
Saieg
MA
,
Troncone
G
,
Zeppa
P
.
Cytological preparations for molecular analysis: a review of technical procedures, advantages and limitations for referring samples for testing
.
Cytopathology
.
2018
;
29
(
2
):
125
32
.
9.
Planchard
D
,
Popat
S
,
Kerr
K
,
Novello
S
,
Smit
EF
,
Faivre-Finn
C
, et al
.
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
.
Ann Oncol
.
2018
;
29
(
Suppl 4
):
iv192
237
.
10.
Caputo
A
,
D’Ardia
A
,
Sabbatino
F
,
Picariello
C
,
Ciaparrone
C
,
Zeppa
P
, et al
.
Testing EGFR with idylla on cytological specimens of lung cancer: a review
.
Int J Mol Sci
.
2021
;
22
(
9
):
4852
.
11.
Smeltzer
MP
,
Wynes
MW
,
Lantuejoul
S
,
Soo
R
,
Ramalingam
SS
,
Varella-Garcia
M
, et al
.
The International Association for the Study of lung cancer global survey on molecular testing in lung cancer
.
J Thorac Oncol
.
2020
;
15
(
9
):
1434
48
.
12.
Chen
X
,
Xu
B
,
Li
Q
,
Xu
X
,
Li
X
,
You
X
, et al
.
Genetic profile of non-small cell lung cancer (NSCLC): a hospital-based survey in Jinhua
.
Mol Genet Genomic Med
.
2020
;
8
(
9
):
e1398
.
13.
Lozano
MD
,
Echeveste
JI
,
Abengozar
M
,
Mejías
LD
,
Idoate
MA
,
Calvo
A
, et al
.
Cytology smears in the era of molecular biomarkers in non-small cell lung cancer: doing more with less
.
Arch Pathol Lab Med
.
2018
;
142
(
3
):
291
8
.
14.
Jain
D
,
Roy-Chowdhuri
S
.
Molecular Pathology of lung cancer cytology specimens: a concise review
.
Arch Pathol Lab Med
.
2018
;
142
(
9
):
1127
33
.
15.
Sung
S
,
Heymann
JJ
,
Crapanzano
JP
,
Moreira
AL
,
Shu
C
,
Bulman
WA
, et al
.
Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management
.
J Am Soc Cytopathol
.
2020
;
9
(
5
):
332
45
.
16.
LINEE GUIDA NEOPLASIE DEL POLMONE
;
AIOM
.
2021
. https://www.aiom.it/linee-guida-aiom-2021-neoplasie-del-polmone/ (accessed August 26, 2024).
17.
Kerr
KM
,
Bibeau
F
,
Thunnissen
E
,
Botling
J
,
Ryška
A
,
Wolf
J
, et al
.
The evolving landscape of biomarker testing for non-small cell lung cancer in Europe
.
Lung Cancer
.
2021
;
154
:
161
75
.
18.
Schmitt
FC
,
Bubendorf
L
,
Canberk
S
,
Chandra
A
,
Cree
IA
,
Engels
M
, et al
.
The World Health Organization reporting system for lung cytopathology
.
Acta Cytol
.
2023
;
67
(
1
):
80
91
.
19.
Bellevicine
C
,
Malapelle
U
,
Vigliar
E
,
Pisapia
P
,
Vita
G
,
Troncone
G
.
How to prepare cytological samples for molecular testing
.
J Clin Pathol
.
2017
;
70
(
10
):
819
26
.
20.
Peña
KB
,
Riu
F
,
Hernandez
A
,
Guilarte
C
,
Elizalde-Horcada
M
,
Parada
D
.
Study of liquid-based cytology using next-generation sequencing as a Liquid biopsy application in patients with advanced oncological disease
.
Biomedicines
.
2023
;
11
(
6
):
1578
.
21.
Dietel
M
,
Bubendorf
L
,
Dingemans
AMC
,
Dooms
C
,
Elmberger
G
,
García
RC
, et al
.
Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group
.
Thorax
.
2016
;
71
(
2
):
177
84
.
22.
Bubendorf
L
,
Lantuejoul
S
,
de Langen
AJ
,
Thunnissen
E
.
Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: number 2 in the Series “Pathology for the clinician” Edited by Peter Dorfmüller and Alberto Cavazza
.
Eur Respir Rev
.
2017
;
26
(
144
):
170007
.
23.
Rolfo
C
,
Mack
P
,
Scagliotti
GV
,
Aggarwal
C
,
Arcila
ME
,
Barlesi
F
, et al
.
Liquid biopsy for advanced NSCLC: a consensus statement from the International association for the study of lung cancer
.
J Thorac Oncol
.
2021
;
16
(
10
):
1647
62
.
24.
Canberk
S
,
Engels
M
.
Cytology samples and molecular biomarker testing in lung cancer-advantages and challenges
.
Virchows Arch
.
2021
;
478
(
1
):
45
57
.
25.
Treece
AL
,
Montgomery
ND
,
Patel
NM
,
Civalier
CJ
,
Dodd
LG
,
Gulley
ML
, et al
.
FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas
.
Cancer Cytopathol
.
2016
;
124
(
6
):
406
14
.
26.
Baum
JE
,
Zhang
P
,
Hoda
RS
,
Geraghty
B
,
Rennert
H
,
Narula
N
, et al
.
Accuracy of next-generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma
.
Cancer Cytopathol
.
2017
;
125
(
6
):
398
406
.
27.
Karnes
HE
,
Duncavage
EJ
,
Bernadt
CT
.
Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung
.
Cancer Cytopathol
.
2014
;
122
(
2
):
104
13
.
28.
Scarpa
A
,
Sikora
K
,
Fassan
M
,
Rachiglio
AM
,
Cappellesso
R
,
Antonello
D
, et al
.
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel
.
PLoS One
.
2013
;
8
(
11
):
e80478
.
29.
Martin-Deleon
R
,
Teixido
C
,
Lucena
CM
,
Martinez
D
,
Fontana
A
,
Reyes
R
, et al
.
EBUS-TBNA cytological samples for comprehensive molecular testing in non-small cell lung cancer
.
Cancers
.
2021
;
13
(
9
):
2084
.
30.
Fassunke
J
,
Büttner
R
,
Engels
M
.
Molecular diagnostics of lung cancer in serous effusion samples
.
J Mol Pathol
.
2022
;
3
(
2
):
78
87
.
31.
Huang
M
,
Wei
S
.
Overview of molecular testing of cytology specimens
.
Acta Cytol
.
2020
;
64
(
1–2
):
136
46
.
32.
Schmitt
F
,
Lozano
MD
.
Molecular/biomarker testing in lung cytology: a practical approach
.
Diagn Cytopathol
.
2023
;
51
(
1
):
59
67
.
33.
Guerra
A
,
Marotta
V
,
Deandrea
M
,
Motta
M
,
Limone
PP
,
Caleo
A
, et al
.
BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma
.
Endocrine
.
2013
;
44
(
1
):
165
71
.
34.
Pang
W
,
Gong
L
,
Shi
W
,
Zheng
H
,
Ye
M
,
Chen
J
, et al
.
Identification of gene variation feature for targeted therapy of non-small cell lung cancer through combined method of DNA and RNA sequencing
.
Discov Oncol
.
2024
;
15
(
1
):
67
.
35.
Gailey
MP
,
Stence
AA
,
Jensen
CS
,
Ma
D
.
Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue
.
Cancer Cytopathol
.
2015
;
123
(
1
):
30
9
.
36.
Planchard
D
,
Remon
J
,
Nowak
F
,
Soria
JC
.
Future genetic/genomic biomarker testing in non–small cell lung cancer
.
Am Soc Clin Oncol Educ Book
.
2017
;
37
(
37
):
12
7
.
You do not currently have access to this content.